Antiangiogenic activity of the selective cyclooxygenase 2 inhibitor rofecoxib in human colorectal cancer liver metastases

被引：9

作者：

Chalmers, C. R.

Wilson, D. J.

Ward, J.

Robinson, P. J.

Toogood, G. J.

Hull, M. A. ^{[1
]}

机构：

[1] Univ Leeds, St Jamess Univ Hosp, Inst Mol Med, Leeds, W Yorkshire, England

[2] St Jamess Univ Hosp, Dept Med Phys, Leeds, W Yorkshire, England

[3] St Jamess Univ Hosp, Dept Radiol, Leeds, W Yorkshire, England

[4] St Jamess Univ Hosp, Dept Hepatobiliary Surg, Leeds, W Yorkshire, England

来源：

GUT | 2006年 / 55卷 / 07期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1136/gut.2005.090571

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1058 / 1059

页数：2

共 11 条

[1] The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases [J].

Fenwick, SW ;

Toogood, GJ ;

Lodge, JPA ;

Hull, MA .

GASTROENTEROLOGY, 2003, 125 (03) :716-729

[2] Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model [J].

Jackson, A ;

Haroon, H ;

Zhu, XP ;

Li, KL ;

Thacker, NA ;

Jayson, G .

NMR IN BIOMEDICINE, 2002, 15 (02) :164-173

[3] Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy [J].

Jain, RK .

SCIENCE, 2005, 307 (5706) :58-62

[4] Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials [J].

Leach, MO ;

Brindle, KM ;

Evelhoch, JL ;

Griffiths, JR ;

Horsman, MR ;

Jackson, A ;

Jayson, G ;

Judson, IR ;

Knopp, MV ;

Maxwell, RJ ;

McIntyre, D ;

Padhani, AR ;

Price, P ;

Rathbone, R ;

Rustin, G ;

Tofts, PS ;

Tozer, GM ;

Vennart, W ;

Waterton, JC ;

Williams, SR ;

Workman, P .

BRITISH JOURNAL OF RADIOLOGY, 2003, 76 :S87-S91

[5] Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance [J].

Ma, L ;

del Soldato, P ;

Wallace, JL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (20) :13243-13247

[6] Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time [J].

Medved, M ;

Karczmar, G ;

Yang, C ;

Dignam, J ;

Gajewski, TF ;

Kindler, H ;

Vokes, E ;

MacEneany, P ;

Mitchell, MT ;

Stadler, WM .

JOURNAL OF MAGNETIC RESONANCE IMAGING, 2004, 20 (01) :122-128

[7] Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases:: Results from two phase I studies [J].

Morgan, B ;

Thomas, AL ;

Drevs, J ;

Hennig, J ;

Buchert, M ;

Jivan, A ;

Horsfield, MA ;

Mross, K ;

Ball, HA ;

Lee, L ;

Mietlowski, W ;

Fuxius, S ;

Unger, C ;

O'Byrne, K ;

Henry, A ;

Cherryman, GR ;

Laurent, D ;

Dugan, M ;

Marmé, D ;

Steward, WP .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3955-3964

[8] Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors [J].

Sund, M ;

Hamano, Y ;

Sugimoto, H ;

Sudhakar, A ;

Soubasakos, M ;

Yerramalla, U ;

Benjamin, LE ;

Lawler, J ;

Kieran, M ;

Shah, A ;

Kalluri, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (08) :2934-2939

[9]

Tofts PS, 1999, J MAGN RESON IMAGING, V10, P223, DOI 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO

[10]

2-S

← 1 2 →